Antibody responses to Helicobacter pylori and risk of developing colorectal cancer in a European cohort

• Main Authors: Butt, Julia, Jenab, Mazda, Pawlita, Michael, Tjonneland, Anne, Kyro, Cecilie, Boutron-Ruault, Marie-Christine, Carbonnel, Franck, Dong, Catherine, Kaaks, Rudolf, Kuhn, Tilman, Boeing, Heiner, Schulze, Matthias B., Trichopoulou, Antonia, Karakatsani, Anna, La Vecchia, Carlo, Palli, Domenico, Agnoli, Claudia, Tumino, Rosario, Sacerdote, Carlotta, Panico, Salvatore, Bueno-de-Mesquita, Bas, Vermeulen, Roel, Gram, Inger T., Weiderpass, Elisabete, Borch, Kristin Benjaminsen, Quiros, Jose Ramon, Agudo, Antonio, Rodriguez-Barranco, Miguel, Santiuste, Carmen, Ardanaz, Eva, Van Guelpen, Bethany, Harlid, Sophia, Imaz, Liher, Perez-Cornago, Aurora, Gunter, Marc J., Zouiouich, Semi, Park, Jin Young, Riboli, Elio, Cross, Amanda J., Heath, Alicia K., Waterboer, Tim, Hughes, David J.
• Format: Article
• Published: American Association for Cancer Research 2020
• Subjects: RC0254 Neoplasms. Tumors. Oncology (including Cancer)
• Online Access: http://eprints.um.edu.my/36564/

Background: While Helicobacter pylori (H. pylori) is the major cause of gastric cancer, it has also been suggested to be involved in colorectal cancer development. However, prospective studies addressing H. pylori and colorectal cancer are sparse and inconclusive. We assessed the association of antibody responses to H. pylori proteins with colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Methods: We applied H. pylori multiplex serology to measure antibody responses to 13 H. pylori proteins in prediagnostic serum samples from 485 colorectal cancer cases and 485 matched controls nested within the EPIC study. Odds ratios (OR) and 95% confidence intervals (CI) were calculated using multivariable conditional logistic regression to estimate the association of H. pylori overall and protein-specific seropositivity with odds of developing colorectal cancer. Results: Fifty-one percent of colorectal cancer cases were H. pylori seropositive compared with 44% of controls, resulting in an OR of 1.36 (95% CI, 1.00-1.85). Among the 13 individual H. pylori proteins, the association was driven mostly by seropositivity to Helicobacter cysteine-rich protein C (HcpC; OR: 1.66; 95% CI, 1.19-2.30) and Vacuolating cytotoxin A (VacA) (OR: 1.34; 95% CI, 0.99-1.82), the latter being nonstatistically significant only in the fully adjusted model. Conclusions: In this prospective multicenter European study, antibody responses to H. pylori proteins, specifically HcpC and VacA, were associated with an increased risk of developing colorectal cancer. Impact: Biological mechanisms for a potential causal role of H. pylori in colorectal carcinogenesis need to be elucidated, and subsequently whether H. pylori eradication may decrease colorectal cancer incidence.